SCHEMBL18448152

SCHEMBL18448152

Cc1ccc(-c2cccc3[nH]c(-c4n[nH]c5ccc(C6=CCNCC6)cc45)cc23)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.42
CLK3 P49761 6/20 0.41
DYRK1A Q13627 6/20 0.41
CLK2 P49760 5/20 0.41
HTR6 P50406 3/20 0.41
HTR7 P34969 2/20 0.41
WNT1 P04628 3/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ITK Q08881 2/20 0.37
TGFBR1 P36897 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTT P42858 1/20 0.36
RAD52 P43351 1/20 0.36
CCNT1 O60563 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18447836 0.90 LRRK2 (0.42) LRRK2CLK3DYRK1ACLK2HTR6
SCHEMBL18482518 0.89 CLK3 (0.48) LRRK2CLK3DYRK1ACLK2WNT1
SCHEMBL18446116 0.88 WNT1 (0.42) LRRK2CLK3DYRK1ACLK2HTR6
SCHEMBL18482628 0.88 WNT1 (0.40) CLK3DYRK1ACLK2HTR6HTR7
SCHEMBL20455454 0.88 LRRK2 (0.45) LRRK2CLK3DYRK1ACLK2HTR6
SCHEMBL18480297 0.87 CDK9 (0.48) LRRK2CLK3DYRK1ACLK2CCNT1
SCHEMBL18447957 0.87 CLK3 (0.46) LRRK2CLK3DYRK1ACLK2HTR6
SCHEMBL18495042 0.86 WNT1 (0.53) CLK3DYRK1ACLK2WNT1TGFBR1
SCHEMBL18445490 0.84 CLK2 (0.46) CLK3DYRK1ACLK2WNT1ITK
SCHEMBL18446311 0.84 DYRK1A (0.46) LRRK2CLK3DYRK1ACLK2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604512-B2 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof SAMUMED, LLC (US) 2020-03-31 US claimed
US-20180222891-A1 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-08-09 US claimed
WO-2017023986-A1 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2017-02-09 WO claimed
US-20180222891-A1 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-08-09 US disclosed
US-20180222891-A1 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222891-A1 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A LRRK2 127/4885CLK3 573/4885DYRK1A 585/4885
US-10604512-B2 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof WNT1, WNT3, WNT3A LRRK2 73/4885CLK3 450/4885DYRK1A 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.